ERBB2 and breast cancer: The BOLERO-2, PrE0102, and GINECO studies demonstrated that everolimus plus endocrine therapy significantly prolonged PFS in postmenopausal HR-positive and HER2-negative advanced BC patients who failed endocrine therapy [75–77].